Literature DB >> 23221041

p40: a p63 isoform useful for lung cancer diagnosis - a review of the physiological and pathological role of p63.

Ana Rita Nobre1, André Albergaria, Fernando Schmitt.   

Abstract

At present, p63, TTF-1, and Napsin-A are the main immunochemical markers used to distinguish squamous cell carcinoma (SCC) from lung adenocarcinoma (ADC). However, studies using antibodies against p63 have demonstrated false-positive results with positivity in some ADC. In contrast, the expression of one of the p63 isoforms (ΔNp63), detected by the antibody p40, is highly specific for SCC. Since most cases of lung cancer are diagnosed in small specimens (cytology/biopsies) and saving material for molecular analysis is mandatory, we recommended the use of p40 (in adjunct with TTF-1 and/or Napsin-A) as the best approach to discriminate SCC and lung ADC. In this paper, we review the physiological and pathological role of p63 isoforms as well as their use as diagnostic markers in lung SCC.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23221041     DOI: 10.1159/000345245

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  18 in total

1.  Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.

Authors:  Thomas E Stinchcombe
Journal:  Curr Treat Options Oncol       Date:  2013-12

Review 2.  Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.

Authors:  Lais Osmani; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Semin Cancer Biol       Date:  2017-11-26       Impact factor: 15.707

3.  Interrogating Bronchoalveolar Lavage Samples via Exclusion-Based Analyte Extraction.

Authors:  Jacob J Tokar; Jay W Warrick; David J Guckenberger; Jamie M Sperger; Joshua M Lang; J Scott Ferguson; David J Beebe
Journal:  SLAS Technol       Date:  2017-03-15       Impact factor: 3.047

4.  The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.

Authors:  Yunfan Ma; Mengying Fan; Liang Dai; Xiaozheng Kang; Yiqiang Liu; Yu Sun; Wanpu Yan; Zhen Liang; Hongchao Xiong; Keneng Chen
Journal:  Tumour Biol       Date:  2015-05-16

5.  Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations.

Authors:  Mohammed T Lilo; Derek Allison; Yuting Wang; MingHui Ao; Edward Gabrielson; Susan Geddes; Hui Zhang; Frederic Askin; Qing Kay Li
Journal:  J Am Soc Cytopathol       Date:  2016 May-Jun

6.  The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.

Authors:  Ming-Hui Ao; Hui Zhang; Lynne Sakowski; Rajni Sharma; Peter B Illei; Edward Gabrielson; Frederic Askin; Qing Kay Li
Journal:  Hum Pathol       Date:  2014-01-25       Impact factor: 3.466

7.  Upper Gastrointestinal Bleed as a Manifestation of Poorly Differentiated Metastatic Squamous Cell Carcinoma of the Lung.

Authors:  Richa Bhardwaj; Gaurav Bhardwaj; Arun Gautam; Raffi Karagozian
Journal:  J Clin Diagn Res       Date:  2017-06-01

8.  Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis.

Authors:  Yunfan Ma; Mengying Fan; Liang Dai; Xiaozheng Kang; Yiqiang Liu; Yu Sun; Hongchao Xiong; Zhen Liang; Wanpu Yan; Keneng Chen
Journal:  Thorac Cancer       Date:  2015-04-24       Impact factor: 3.500

9.  Cancer RNA-Seq Nexus: a database of phenotype-specific transcriptome profiling in cancer cells.

Authors:  Jian-Rong Li; Chuan-Hu Sun; Wenyuan Li; Rou-Fang Chao; Chieh-Chen Huang; Xianghong Jasmine Zhou; Chun-Chi Liu
Journal:  Nucleic Acids Res       Date:  2015-11-23       Impact factor: 19.160

Review 10.  Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective.

Authors:  Elisa Brega; Guilherme Brandao
Journal:  Front Oncol       Date:  2014-07-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.